VERINA: A Phase IV Prospective Multicenter Study of Vericiguat in Indian Patients with Worsening Heart Failure and Reduced Ejection Fraction
Authors:
Open Access
- 20 October 2026
- journal article
- research article
- Published by Springer Nature in Cardiology and Therapy
- Vol. 15 (4) , 621-635
Abstract
Introduction Patients with heart failure (HF) with reduced ejection fraction (HFrEF) remain at high risk of cardiovascular (CV) death and hospitalization following a worsening heart-failure event. Data on vericiguat, a prescription oral medication used to treat symptomatic chronic HF, in adult Indian patients are limited. Methods Adults with chronic HFrEF and a worsening heart-failure event were enrolled in a prospective, multicenter, open-label, single-arm phase IV study design. Participants received vericiguat in addition to foundational medical therapy (FMT) and were followed for approximately 48 weeks. The primary endpoint was CV death or first hospitalization for HF. Secondary endpoints included CV death, first hospitalization for HF, all-cause death or first hospitalization for HF, all-cause death and safety outcomes. Results Of 231 patients who underwent screening, 205 received vericiguat and comprised the safety analysis set; of these, 203 patients constituted the full analysis set. The mean age of participants was 58 years. Baseline use of angiotensin receptor–neprilysin inhibitors and sodium–glucose cotransporter-2 inhibitors was 52.7% and 75.6%, respectively. At week 48, Kaplan–Meier (KM) estimates were 10.1% for the primary endpoint, 3.3% for CV death, 9.1% for first hospitalization for HF, 11.5% for all-cause death or first hospitalization for HF, and 5.9% for all-cause death. Attainment of the target dose was 91.6%, with 69.5% of participants reaching and maintaining 10 mg by week 4. Study drug-related adverse events (AEs) were reported in 3.4% of participants, and treatment-emergent AEs requiring discontinuation in 2.0% of participants. Conclusion In Indian patients with worsening HFrEF, high target-dose attainment and no new safety signals were observed during 48 weeks of vericiguat treatment. Trial Registration Clinical Trials Registry–India: CTRI/2022/11/047636.Keywords
This publication has 32 references indexed in Scilit:
- Study Design and Baseline Characteristics of the VERINA Study: Phase IV Evidence of Vericiguat for Worsening Heart Failure ManagementCardiology and Therapy, 2025
- Clinical Profile, Associated Events and Safety of Vericiguat in a Real-World Cohort: The VERITA StudyESC Heart Failure, 2024
- Management of Heart Failure in a Resource-Limited Setting: Expert Opinion from IndiaCardiology and Therapy, 2024
- Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in GermanyEuropean Journal of Clinical Pharmacology, 2024
- Clinical Profile and 90 Day Outcomes of 10 851 Heart Failure Patients Across India: National Heart Failure RegistryESC Heart Failure, 2022
- Vericiguat and NT-proBNP in Patients with Heart Failure with Reduced Ejection Fraction: Analyses from the VICTORIA TrialESC Heart Failure, 2022
- Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trialEuropean Journal of Heart Failure, 2022
- Clinical Outcomes and Response to Vericiguat According to Index Heart Failure EventJAMA Cardiology, 2021
- Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA ( Vericiguat Global Study in Subjects with HFrEF ) trialEuropean Journal of Heart Failure, 2021
- Baseline Features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) TrialEuropean Journal of Heart Failure, 2019